ANI Pharmaceuticals (ANIP) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings or view top-rated stocks.

3 analysts have issued twelve-month target prices for ANI Pharmaceuticals' stock. Their ANIP share price forecasts range from $48.00 to $60.00. On average, they anticipate the company's share price to reach $55.67 in the next twelve months. This suggests a possible upside of 16.0% from the stock's current price.
View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts.

ANI Pharmaceuticals' stock was trading at $40.23 at the beginning of the year. Since then, ANIP stock has increased by 19.3% and is now trading at $48.00.
View the best growth stocks for 2023 here.

ANI Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 336,900 shares, a decline of 15.9% from the April 30th total of 400,700 shares. Based on an average daily volume of 104,000 shares, the days-to-cover ratio is presently 3.2 days.
View ANI Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our ANIP earnings forecast.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its quarterly earnings data on Thursday, March, 9th. The specialty pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.10. The specialty pharmaceutical company had revenue of $94.23 million for the quarter, compared to analysts' expectations of $86.76 million. ANI Pharmaceuticals had a negative net margin of 7.34% and a positive trailing twelve-month return on equity of 10.60%.

ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Pharmaceuticals ETF (XPH), Syntax Stratified SmallCap ETF (SSLY), Principal Healthcare Innovators ETF (BTEC), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and

ANI Pharmaceuticals updated its FY 2023 earnings guidance on Monday, May, 8th. The company provided earnings per share (EPS) guidance of $2.99-$3.45 for the period, compared to the consensus EPS estimate of $2.43. The company issued revenue guidance of $385.00 million-$410.00 million, compared to the consensus revenue estimate of $361.82 million.

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

ANI Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.10%), Rubric Capital Management LP (3.61%), Dimensional Fund Advisors LP (3.04%), William Blair Investment Management LLC (3.02%), Global Alpha Capital Management Ltd. (2.65%) and State Street Corp (2.56%). Insiders that own company stock include James G Marken, Jeanne Thoma, Muthusamy Shanmugam, Nikhil Lalwani, Patrick D Walsh and Thomas Haughey.
View institutional ownership trends.

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANIP stock can currently be purchased for approximately $48.00.

ANI Pharmaceuticals (NASDAQ:ANIP) has a market capitalization of $862.56 million and generates $316.39 million in revenue each year. The specialty pharmaceutical company earns $-47,900,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

The company employs 601 workers across the globe.

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The official website for the company is www.anipharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at ir@anipharmaceuticals.com, or via fax at 218-634-3540.